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Injury to peripheral nerves often results in a persistent neuropathic pain condition that is characterized by spontaneous pain, allodynia,
and hyperalgesia. Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release
several pronociceptive mediators. Kinin B1 receptors are rarely expressed in nontraumatized tissues, but they can be expressed after
tissue injury. Because B1 receptors mediate chronic inflammatory painful processes, we studied their participation in neuropathic pain
using receptor gene-deleted mice. In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal or
mechanical stimulationbetweenB1 receptor knock-outmice and129/Jwild-typemice. Partial ligation of the sciatic nerve in thewild-type
mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion.
Threshold changed neither in the sham-operated animals nor in the paw contralateral to lesion. Ablation of the gene for the B1 receptor
resulted in a significant reduction in early stages of mechanical allodynia and thermal hyperalgesia. Furthermore, systemic treatment
with theB1 selective receptor antagonistdes-Arg
9-[Leu8]-bradykinin reduced theestablishedmechanical allodyniaobserved7–28dafter
nerve lesion inwild-typemice. Partial sciatic nerve ligation inducedanupregulation inB1 receptormRNA in ipsilateral paw, sciatic nerve,
and spinal cord of wild-type mice. Together, kinin B1 receptor activation seems to be essential to neuropathic pain development,
suggesting that an oral-selective B1 receptor antagonist might have therapeutic potential in the management of chronic pain.
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Introduction
Injury to a peripheral nerve in humans often results in a persis-
tent neuropathic pain condition that is characterized by sponta-
neous pain, allodynia (pain responses to non-noxious stimuli),
and hyperalgesia (exaggerated pain responses to noxious stimuli)
(Malmberg andBasbaum, 1998). This type of chronic pain differs
substantially from acute pain not only in terms of the persistence
of pain but also with regard to the maladaptive changes, such as
neuroplasticity, that have been described at various levels of the
nervous system (Besson, 1999). Thus, the available analgesic
drugs often have limited therapeutic value in the management of
chronic pain and they may, in fact, represent a risk to the patient
because of their common side effects (Woolf and Mannion,
1999). Therefore, the development of safe and efficacious drugs
to treat chronic pain is an urgent priority.
Nerve injury is accompanied by a local inflammatory reaction
in which nerve-associated and immune cells release several
pronociceptive mediators such as cytokines, eicosanoids, and ki-
nins (Tracey and Walker, 1995; Bennett, 1999). Of note, in-
creased serum bradykinin levels have been found in patients with
neuropathic pain (Blair et al., 1998).
Kinins are peptides formed in plasma and peripheral tissues in
response to the activation of a class of enzymes, denoted “kal-
likreins,” on kininogen substrates. Kinins are involved in a wide
range of physiological mechanisms, including control of blood
pressure, smooth-muscle contraction or relaxation, vascular per-
meability, and pain transmission. Furthermore, kinins are impli-
cated in pathological states such as arthritis, pancreatitis, and
asthma (for review, see Calixto et al., 2000, 2004). The actions of
kinins are mediated through the stimulation of two subtypes of
G-protein-coupled receptors, denoted B1 and B2. The kinin B1
receptors exhibit higher affinity for the carboxypeptidase metab-
olites of kinins, des-Arg9-bradykinin and des-Arg10-kallidin.
Usually, the B1 receptors are hardly expressed in nontraumatized
tissues, but they can be expressed under certain conditions, such
as those after tissue injury and infection (for review, see Marceau
et al., 1998). In contrast, the B2 receptors for which bradykinin
and kallidin exhibit great affinity are usually constitutively ex-
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pressed andwidely distributed throughout central and peripheral
tissues (for review, see Calixto et al., 2000, 2004).
Once formed in the periphery, kinins activate A and C fibers
in sensory nerves producing pain, hyperalgesia, or allodynia in
both humans and experimental animals. In addition, kinins may
cause the release of other mediators such as neurokinins, calcito-
nin gene-related peptide, nitric oxide, and arachidonic acid me-
tabolites, which also account for primarily their proinflamma-
tory and nociceptive properties (for review, see Calixto et al.,
2000, 2004) (Dray and Perkins, 1997).
Recently, the use of both B1 and B2 knock-out mice has led to
a better understanding of the role played by kinins in physiolog-
ical and pathological processes (Borkowski et al., 1995; Pesquero
et al., 2000). For example, the deletion of the B1 receptor gene
significantly decreases acute and chronic inflammatory nocicep-
tion (Pesquero et al., 2000; Ferreira et al., 2001, 2002). In the
present study, we examine the contribution of the kinin B1 recep-
tor to the chronic nociception produced by peripheral nerve in-
jury using knock-outmice, selective drugs, and themeasurement
of mRNA levels.
Materials andMethods
Animals. Experiments were conducted using male and female wild-type
129/J mice and kinin B1 receptor knock-out mice (20–30 g; 129/J back-
ground) kept at controlled room temperature (22  2°C) under a 12 h
light/dark cycle (lights on at 6:00 A.M.) and 60–90% humidity. The
animals were obtained from the Department of Biophysics at the Federal
University of Sa˜o Paulo (Brazil). Deletion of the entire coding sequence
for the kinin B1 receptor was achieved as described previously (Pesquero
et al., 2000). The experiments were performed in accordance with cur-
rent guidelines for the care of laboratory animals and ethical guidelines
for the investigation of pain in conscious animals (Zimmermann, 1983).
The number of animals and intensity of noxious stimuli used were the
minimum necessary to demonstrate the consistent effects of drug treat-
ments or genetic manipulation.
Partial sciatic nerve ligation. For the induction of chronic neuropathy,
male and female mice were anesthetized by intraperitoneal injection of
7% chloral hydrate (0.6 ml/kg; Vetec, Rio de Janeiro, Brazil). A partial
ligation of the right sciatic nerve wasmade by tying one-third to one-half
of the dorsal portion of the sciatic nerve, using a similar procedure to that
described for rats by Seltzer et al. (1990) and for mice by Malmberg and
Basbaum (1998). In sham-operatedmice, the nerve was exposed without
ligation.
Measurement of thermal hyperalgesia. Thermal hyperalgesia was mea-
sured using the paw-withdrawal latency according to the method de-
scribed by Hargreaves et al. (1988), with minor modifications. After
challenge, hyperalgesia was measured at several time points after nerve
injury (1–42 d), as described below. Thermal baseline measures were
obtained from nonoperated animals 1 d before nerve injury. Mice were
placed in clear plastic chambers (7 9 11 cm) on an elevated surface
and allowed to acclimatize to their environment for 1.5 h before testing.
The heat stimulus was directed to the plantar surface of each hindpaw in
the area immediately proximal to the toes. The infrared intensity was
adjusted to obtain basal paw-withdrawal latencies of 11 s. An auto-
matic 20 s cutoff was used to prevent tissue damage.
Measurement of mechanical allodynia.Mechanical nociceptive thresh-
olds in mice were measured as the withdrawal response frequency to
application of von Frey hairs (Stoelting, Chicago, IL). Six hairs with
forces of 0.07, 0.16, 0.6, 1, 2, and 4 g were applied 10 times each to the
plantar surface of each hindpaw following an alternating sequence and in
ascending order of force. Themonofilamentwas applied at intervals of 2 s
to slightly different loci on the plantar surface of both hindpaws. A pos-
itive withdrawal response was considered valid only when the hindpaw
was completely removed from the platform. The frequency of positive
responses was calculated after 10 applications of the filament. The fre-
quency of response was measured before and 1–42 d after nerve injury.
Mechanical baseline measures were obtained from nonoperated animals
1 d before nerve injury. Mice were placed individually in clear Plexiglas
boxes (9 7 11 cm) on elevatedwiremesh platforms to allow access to
the ventral surface of the hindpaws. Animals were acclimatized to the
testing chambers, and the static mechanical withdrawal threshold was
determined before and after nerve injury. The involvement of the B1
receptor in mechanical allodynia was tested by using the selective antag-
onist of the B1 receptor des-Arg
9-[Leu8]-bradykinin (150 nmol/kg, s.c.;
Sigma, St. Louis, MO) (Ferreira et al., 2001).
Quantitative real-time PCR. The expression of B1 receptor mRNA was
measured using a quantitative real-time PCR according to the method
described previously (Argan˜araz et al., 2004). Several days after nerve
lesion, mice (n 3–6 for each group) were killed, and the plantar skin of
the right hindpaw, right sciatic nerve, dorsal portion of spinal cord, and
whole cerebral cortex were isolated, dissected, and frozen in liquid nitro-
gen and stored at80°C. Thawed tissue was homogenized in 0.3–1ml of
TRIzol reagent (Invitrogen, Gaithersburg, MD), and total RNA was iso-
lated according to the instructions of the manufacturer. Before cDNA
synthesis, RNA samples were pretreated with DNase I (Invitrogen) to
avoid genomic DNA contamination. Reverse transcription was per-
formed using 2g of total pure RNA, 50 ng of randomhexamer primers,
and 200 U of Maloney murine leukemia virus reverse transcriptase (In-
vitrogen), as described by themanufacturers. Samples were submitted to
a 20l reaction using TaqManAmplification systemwith an ABI PRISM
7000 Sequence Detection system (Applied Biosystems, Foster City, CA).
Multiplex reactions were performed with 600 ng of cDNA for kinin B1
receptor and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) am-
plification. Oligonucleotide primers and fluorogenic probe sets for Taq-
Man real-time PCRwere designed for kinin B1 receptor using Assays-by-
Design service (Applied Biosystems) to meet all TaqMan design
guidelines. The probes were synthesized with the reporter dye
6-carboxyfluorescein (6-FAM) covalently linked at the 5-end, and the
quencher dye 6-carboxy-tetramethyl-rhodamine was linked to the 3-
end of the probe. For GAPDH amplification, commercial TaqMan ro-
dent GAPDH control reagents (Applied Biosystems) were used. Differ-
ently from kinin B1 receptor probe, the GAPDH probe was VIC-labeled,
allowing us to use it for multiplex detection. Each reaction was per-
formed with 10 l of Master Mix (Applied Biosystems), 1 l of a mix
containing two primers (18 M each) and a probe (5 M) specific to
mRNA of kinin B1 receptor (probe B1: 5-CACAGGAACCCAGACAG-3,
forward primer: 5-CCATACAAAACCCCAGCTGAA-3, reverse primer:
5-CTTTGGTTAGAAGGCTGTAGCTTCA-3), and 1 l of each GAPDH
primer and the VIC-labeled probe (10M each). The cycle conditions were
as follows: 50°C for 2min and then 95°C for 10min, followed by 50 cycles of
95°C for 15 s (melting step), and 60°C for 1min (anneal/extend step). Both
FAMandVIC correspondent fluorescenceswere acquired at the endof each
extend phase. The PCR cycle, when a given fluorescence threshold is crossed
by the amplification curve, was considered our first parameter to analyze
mRNAexpression andnamedCt.Ct valueswere calculated by subtracting
GAPDHCt fromkininB1 receptorCt toobtain the2
Ct parameter,which
represents relative B1 receptor/GAPDH expression.
Measurement of overt nociception. The procedure used was similar to
that described previously (Ferreira et al., 2004). Twenty microliters of
des-Arg9-bradykinin solution (10 nmol/paw; Sigma) were injected in-
traplantarly under the surface of the right hindpaw 7 d after sham surgery
or partial sciatic nerve lesion in wild-type mice. Separate groups of ani-
mals received an intraplantar injection of vehicle (PBS). Animals were
placed individually in chambers (transparent glass cylinders of 20 cm
diameter) and were adapted for 20 min before algogen or vehicle injec-
tion. After challenge, mice were observed individually for 10 min. The
amount of time spent licking the injected paw was measured with a
chronometer and was considered as indicative of overt nociception.
Skin temperature measurement. Apart from nociceptive hypersensitiv-
ity, sciatic nerve lesions may cause abnormal cutaneous temperature
regulation. Thus, the skin temperature of the ipsilateral and contralateral
paw was measured 7 d after surgery using a surface radiation thermom-
eter (Pro Check, Taipei, Taiwan) as described previously (Ferreira et al.,
2004).
Data analysis. The results are presented as means SEM of four to six
animals. The statistical significance of differences between groups was
2406 • J. Neurosci., March 2, 2005 • 25(9):2405–2412 Ferreira et al. • Neuropathic Pain in Kinin B1 Receptor Knock-Out Mice
analyzed by means of Student’s t test or ANOVA followed by Student–
Newman–Keuls test when appropriate. p values 0.05 were considered
indicative of significance.
Results
Partial ligation of the sciatic nerve in the wild-type mouse pro-
duced a profound and prolonged decrease in thermal and me-
chanical nociceptive thresholds observed in the paw ipsilateral to
the nerve lesion (Figs. 1, 2). Neither threshold changed in the
sham-operated animals or in the paw contralateral to the lesion
(Figs. 1, 2). We found a significant reduction in the paw-
withdrawal latency to the heat stimulus as early as 1 d after nerve
injury that was stable until 21 d compared with sham-operated
wild-type animals (Fig. 1A). At 28 d after the nerve injury, the
paw-withdrawal latencies to thermal stimulation returned to
baseline values (Fig. 1A).
In the absence of neuropathy, we found no difference in the
paw-withdrawal responses to thermal stimulation between B1
receptor knock-out mice and wild-type mice (10.3  0.7 and
10.5 0.6 s, respectively). Ablation of the gene for the B1 receptor
caused a significant reduction in thermal hyperalgesia produced
by nerve injury (Fig. 1A). This anti-hyperalgesic response was
observed from 1 to 21 d after lesion.
Before nerve injury, wild-type mice showed an increase in the
frequency of responses to mechanical stimulation with von Frey
hairs of higher forces (1–4 g) but little change in the responses to
weaker von Frey hairs (0.07–0.6 g) (Fig. 2A). Moreover, B1 re-
ceptor knock-out mice displayed a similar pattern of response to
high and weak mechanical stimulation (Fig. 2A). Thus, von Frey
hairs from 0.07 to 0.6 g were considered innocuous stimuli for
both wild-type and B1 receptor knock-out mice.
Mechanical allodynia produced by nerve injury was charac-
terized by a pronounced and long-lasting increase in response
frequency to innocuous von Frey hairs stimulation in the paw
ipsilateral to the lesion (Fig. 2B). In contrast to thermal hyperal-
Figure 1. Time-dependent thermal hyperalgesia in the ipsilateral paw (A) but not in con-
tralateral paw (B) induced by partial sciatic nerve lesion (PSNL) in wild-type (	/	) or B1
receptor knock-out (/)mice. Data represent the latencies of the response to thermal stim-
uli. Each point represents themean SEM of four to six mice. In some cases, the error bars are
hidden within the symbols. *p 0.05 or **p 0.01 denotes the significance level when
compared with the wild-type sham-operated group. #p  0.05 or ##p  0.01 denotes
the significance level when compared with the wild-type PSNL group (one-way ANOVA fol-
lowed by Student–Newman–Keuls test).
Figure 2. A, Mechanical sensitivity to von Frey hairs stimulation in wild-type (	/	) or B1
receptor knock-out (KO) (/)micebeforenerve injury.B, Increasedmechanical sensitivity in
the ipsilateral paw observed 7 d after partial sciatic nerve lesion (PSNL) in wild-type mice
(	/	) but not in B1 receptor knock-out mice (/). Data represent the response frequency
tomechanical stimuli. Each point represents themean SEMof four to sixmice. In some cases,
the error bars are hiddenwithin the symbols. *p 0.05 or **p 0.01 denotes the significance
level when compared with the wild-type sham-operated group. #p 0.05 or ##p 0.01
denotes the significance levelwhen comparedwith thewild-typePSNLgroup (one-wayANOVA
followed by Student–Newman–Keuls test).
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gesia, mechanical allodynia developed at day 1, reached a maxi-
mum at day 7 after nerve ligation, and remained increased for

42 d (Fig. 3A). B1 receptor gene deletion completely reversed
mechanical allodynia from 1 to 28 d after nerve injury (Fig. 3A).
However, this anti-allodynic effect became only partial 35 d after
lesion anddisappeared at day 42 (Fig. 3B).Moreover, wewere not
able to detect mechanical allodynia in the contralateral paw (data
not shown).
To further confirm the participation of the B1 receptor in
neuropathic pain, a separate group of wild-type mice was treated
with the selective B1 receptor antagonist des-Arg
9-[Leu8]-
bradykinin (150 nmol/kg, s.c.). Des-Arg9-[Leu8]-bradykinin ad-
ministration to wild-type mice 7 d after partial sciatic nerve liga-
tion, when the maximal pain hypersensitivity is already installed,
also greatly reduced the mechanical allodynia (Fig. 4). The an-
tinociceptive effect of des-Arg9-[Leu8]-bradykinin was short-
lasting, maximal 1 h after treatment (inhibition of 69.6 5.9%).
In agreement with that after gene deletion, this dose of antagonist
did not alter the frequency responses of mechanical stimulation
of sham-operated animals (50 5.7 and 45 5.0% of frequency
responses against 2.0 g of stimulation when assessed 7 d after
injury). As occurred for the gene lacking, the treatment with
des-Arg9-[Leu8]-bradykinin was also capable of reducing me-
chanical allodynia when the antagonist was administered 14 and
28 d, but not 42 d, after nerve injury (Fig. 4B).
Next, the expression of B1 receptor mRNA was quantified by
real-time reverse transcription (RT)-PCR in tissues of mice after
sciatic nerve lesion or sham operation. Basal expression of B1
receptor mRNA was detected in plantar hindpaw skin, sciatic
nerve, spinal cord, and cerebral cortex of wild-type mice (Fig. 5).
However, 7 d after nerve lesion, we observed an increased of B1
expression in ipsilateral paw skin, right sciatic nerve, and spinal
cord obtained from operated mice (Fig. 5). No expression of B1
receptor mRNA could be detected in B1 receptor gene-deficient
mice (results not shown).Moreover, the increase of expression of
B1 receptor mRNAwas also detected in paw skin of injured wild-
type mice 14, 28, and 42 d after nerve injury (441  216, 241 
Figure 3. Time-dependent mechanical allodynia in ipsilateral paw (A) but not in contralat-
eral paw(B) inducedbypartial sciatic nerve lesion inwild-type (	/	) orB1 receptor knock-out
(/) mice. Data represent the frequency response to 0.16 g von Frey hair stimulation. Each
point represents the mean SEM of four to six mice. In some cases, the error bars are hidden
within the symbols. *p 0.05 or **p 0.01 denotes the significance level when compared
with the wild-type sham-operated group. #p 0.05 or ##p 0.01 denotes the significance
level when compared with the wild-type partial sciatic nerve lesion group (one-way ANOVA
followed by Student–Newman–Keuls test).
Figure 4. Antinociception produced by treatment with the selective B1 receptor antagonist
des-Arg 9-[Leu 8]-bradykinin (DALBK; 150 nmol/kg) in mechanical allodynia in the ipsilateral
paw observed after partial sciatic nerve lesion in wild-type mice. A, Time course of the anti-
allodynic effect 7 d after surgery. B, Anti-allodynic effect of DALBK 7–42 d after nerve injury
when administered 1 h before mechanical allodynia measurement. Data represent the fre-
quency response to 0.16 g von Frey hair (VFH) stimulation. Each point represents the mean
SEMof five to sixmice. *p 0.05 or **p 0.01 denotes the significance level when compared
with PBS-treated mice. ##p 0.01 denotes the significance level when compared with base-
line (B) valuewithout hair stimulation (one-way ANOVA followed by Student–Newman–Keuls
test). The point 0 on the x-axis represents the measured mechanical allodynia immediately
before drug treatment.
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127, 849  103% of increase over sham-operated animals, re-
spectively). These results suggested that the increase in mRNA
appears to mainly relate with the development and the mainte-
nance of early stages of neuropathic pain but not with the main-
tenance of its late stage. In fact, intraplantar injection of the se-
lective B1 receptor agonist des-Arg
9-bradykinin produced overt
nociception in ligated but not in, when assessed, sham-operated
wild-type mice 7 d after surgery (Fig. 6A).
In addition to nociceptive hypersensitivity, other symptoms
similar to clinical features of human neuropathies may occur
after partial sciatic nerve ligation in mice, including abnormal
cutaneous temperature regulation. Accordingly, we observed a
significant increase in the skin surface temperature of the ipsilat-
eral paw 7 d after nerve injury in wild-type mice (Fig. 6B). Nota-
bly, the B1 receptor gene deletion abolished this cutaneous heat-
ing (Fig. 6B). However, we were not able to detect significant
modifications in skin temperature from 14 to 42 d after nerve
injury either in operated or in sham-operated animals (results
not shown).
Discussion
Painful neuropathies may result from nerve injury as well as the
effects of drugs, diseases, toxins, and metabolic disorders (Woolf
andMannion, 1999). Because of the as yet poor understanding of
the mechanisms underlying these syndromes, therapy does not
provide satisfactory pain relief for many patients. Consequently,
these patients suffer from chronic intractable pain (Seltzer,
1995).
Several studies have demonstrated the participation of kinins
and their receptors in neuropathic pain induction. Increased lev-
els of B1 and B2 receptor mRNA or protein have been found in
dorsal root ganglia (DRGs) after sciatic nerve constriction in rats
and mice (Petersen et al., 1998; Eckert et al., 1999; Levy and
Zochodne, 2000; Yamaguchi-Sase et al., 2003; Rashid et al.,
2004). Of note, the systemic administration of B1 or B2 receptor
antagonists has been found to reduce thermal hyperalgesia and
mechanical allodynia produced by sciatic nerve constriction in
rats (Levy and Zochodne, 2000; Yamaguchi-Sase et al., 2003;
Gougat et al., 2004). Plasma seems to be the main source of en-
dogenous kinins after nerve injury, and there is recent evidence
demonstrated that neuropathic pain is reduced inmutant plasma
kininogen-deficient B/N-Katholiek rats when compared with
normal B/N-Kitasato rats (Yamaguchi-Sase et al., 2003).
The present work extended these previous observations by
demonstrating that gene deletion or pharmacological inhibition
of the B1 receptor in mice practically abolished the nociceptive
hypersensitivity produced by nerve injury. This effect appeared as
early as 1 d after lesion, and it was found significant until 28 d
after the surgery, suggesting that the B1 receptor is critically in-
volved in both the development and the early maintenance of
neuropathic pain symptoms. In contrast, thermal hyperalgesia
was not observed, and mechanical allodynia was reduced only in
the later stages of nerve injury (35–42 d after surgery), despite the
detection of increased levels of B1 receptor mRNA. Interestingly,
at this time, the mechanical allodynia was reinstalled in B1 recep-
tor knock-out mice, and the B1 receptor antagonist was not ca-
pable of reducing allodynia. Because regeneration occurs after
constrictive injury to the sciatic nerve (Myers et al., 1996), it is
quite possible that under this circumstance, B1 receptor activity is
Figure 5. Levels of expression of kinin B1 receptor mRNA in the paw skin (A), sciatic nerve
(B), spinal cord (C), and cerebral cortex (D) 7 d after sham surgery or partial sciatic nerve
ligation (PSNL) inwild-typemice (	/	) assessedby real-timeRT-PCRassay.Alldatahavebeen
normalizedfor levelsofGAPDHexpressionwithinthesamesample.Eachbarrepresentsthemean
SEMof three to sixmice. *p 0.05 denotes the significance level when comparedwith the sham-
operated group (Student’s t test).
Figure 6. A, Overt nociception produced by intraplantar injection of des-Arg 9-bradykinin
(DABK; 10 nmol per paw) in wild-type mice (	/	) 7 d after partial sciatic nerve ligation
(PSNL). B, Difference in temperature [ Temperature (°C)] between ipsilateral and contralat-
eral hindpaw surface observed 7 d after unilateral sciatic nerve lesion. Each point represents the
mean SEM of four to six mice. **p 0.01 denotes the significance level when compared
with wild-type sham-operated group. ##p 0.01 denotes the significance level when com-
paredwithwild-typePSNLgroup (one-wayANOVA followedbyStudent–Newman–Keuls test).
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not relevant to the production of neuropathic pain and probably
other mediators substitute for the nociceptive action of kinins.
Pain is produced by the stimulation of small-diameter pri-
mary afferent fibers that innervate regions of the head and body
and arise from cell bodies in the trigeminal ganglion and DRG,
respectively (Julius and Basbaum, 2001). B1 receptor mRNA and
protein are constitutively expressed in mouse, rat, and monkey
DRG (Seabrook et al., 1997; Levy and Zochodne, 2000; Ma et al.,
2000; Wotherspoon and Winter, 2000; Shughrue et al., 2003;
Yamaguchi-Sase et al., 2003; Rashid et al., 2004). B1 receptors are
predominantly expressed by small-diameter DRG neurons colo-
calized with isolectin B4 and calcitonin gene-related peptide that
are contained in C and A fibers (Ma, 2001). Moreover, the B1
receptor is expressed in both peripheral and spinal terminals of
primary afferent fibers (Wotherspoon andWinter, 2000; Ma and
Heavens, 2001; Shughrue et al., 2003). B1 receptors are newly
expressed 7 d after partial sciatic nerve injury in mice mainly in
non-neuronal satellite cells and in largemyelinatedDRGneurons
(Rashid et al., 2004). Because there is evidence that large A fibers
mediate themechanical allodynia in rats with partial sciatic nerve
lesion (Shir and Seltzer, 1990) and B1 receptor knock-out mice
have reduced allodynia, it seems that this novel expression of B1
receptors is potentially related to the production of the persistent
mechanical allodynia observed in the early stages of neuropathy.
In the present study, we have shown that B1 receptor mRNA
was normally expressed in some tissues important for the detec-
tion, transmission, and modulation of pain, including plantar
paw skin, sciatic nerve, spinal cord, and cerebral cortex. More-
over, the involvement of B1 receptors in neuropathy was further
confirmed by the upregulation of B1 receptormRNA several days
after sciatic nerve injury. It has been well demonstrated that sev-
eral stimuli are able to upregulate B1 receptor, including proin-
flammatory cytokines, mitogen-activated protein kinases
(MAPK), and nuclear factor B (NFB) (for review, see Calixto
et al., 2000, 2004).We can suggest that similarmechanismsmight
be involved in B1 receptor upregulation in the present study,
because proinflammatory cytokines are produced, and MAPK
and NFB are activated after sciatic nerve injury (Ma and Bisby,
1998; Okamoto et al., 2001; Ma and Quirion, 2002). We also
observed an increase in levels of B1 receptor mRNA in samples of
ipsilateral paw skin and sciatic nerve 7 d after injury, a finding
that could suggest a role for B1 receptors in the abnormal percep-
tion of noxious and innocuous stimuli seen in early stages neu-
ropathy. This upregulation seems to be functional, because the
intraplantar injection of the selective B1 receptor agonist des-
Arg9-bradykinin produced overt nociception in nerve-injured,
but not in sham-operated, wild-typemice. These results reinforce
the recent data obtained by Rashid et al. (2004), showing that
intraplantar administration of des-Arg10-kallidin was able to in-
duce both nociceptive reflex and activation of ERK (extracellular
signal-regulated kinase) in DRG neurons in ligated, but not
sham-operated, mice.
B1 receptors are also found in the CNS, which contains all of
the components of the kallikrein-kinin system and is also in-
volved in nociceptive processing (Couture and Lindsey, 2000;
Ferreira et al., 2002). B1 receptors have been identified in the
superficial layers of the dorsal horn confined mainly to the ter-
minals of primary sensory nerve fibers (Couture and Lindsey,
2000; Wotherspoon and Winter, 2000). Using an in vitro spinal
cord preparation, Pesquero et al. (2000) demonstrated that B1
receptor stimulation increases the C-fiber component, but not
the A-fiber component, of the ventral root potential produced
by electrical excitation of the dorsal root of naive mice. This
indicates that the B1 receptor functions specifically in nociceptive
synaptic pathways and appears to be involved in some forms of
central sensitization. In fact, intrathecal injection of B1 receptor
antagonists reduces the inflammatory phase of formalin-induced
pain and chronic inflammatory pain caused by Complete
Freund’s Adjuvant in mice and rats (Ferreira et al., 2002; Fox et
al., 2003). Moreover, the use-dependent facilitation of spinal
cord neuron firing (wind-up) was significantly reduced (50%)
in B1 receptor knock-out mice when compared with the wild-
type littermates (Pesquero et al., 2000). We have shown that B1
receptor mRNA is upregulated in dorsal spinal cord after partial
sciatic nerve lesion, further suggesting a role for spinal B1 recep-
tors in neuropathy. Because the development of spinal sensitiza-
tion is an important consequence of nerve injury (Sah et al.,
2003), these data indicate that the nociceptive impairment ob-
served in B1 receptor knock-out mice might be attributed to, at
least in part, a deficit in the pathological plasticity of the spinal
neurons.
Subsets of dorsal horn neurons that project axons and trans-
mit pain messages to higher brain structures are involved in the
somatic, affective, and autonomic responses to pain (Hunt and
Mantyh, 2001). In this respect, we have shown that B1 receptor
mRNA is constitutively expressed in the cerebral cortex of mice.
This result is in line with literature showing basal B1 receptor
expression in rat somatosensory cortex (Ongali et al., 2003;
Shughrue et al., 2003). However, the function of cortical B1 re-
ceptors still remains obscure.
Besides thermal and mechanical hypersensitivity, animals
subjected to sciatic nerve injury exhibit other signs similar to
clinical features of human painful neuropathies, including ab-
normal sympathetic activity, abnormal growth of hair, and cuta-
neous temperature regulation (Wakisaka et al., 1994). Similar to
our observations inmice, the ipsilateral plantar surface in ratswas
warmer than that of the contralateral paw during the first week
after loose ligation of sciatic nerve, thereafter becoming cooler
(Wakisaka et al., 1991, 1994). It has been reported that early
heating of the paw surface is dependent on sympathetic vasocon-
striction (Wakisaka et al., 1994). Furthermore, partial nerve
injury-induced pain is mediated by sympathetic activity (Shir
and Seltzer, 1991; Malmberg and Basbaum, 1998). Interestingly,
functional B1 receptors are expressed in sympathetic neurons,
because their activation by agonists is able to depolarize superior
cervical ganglia neurons in vitro (Seabrook et al., 1995, 1997). In
addition, postganglionic sympathetic terminals are involved in
B1 receptor agonist-induced hyperalgesia (Khasar et al., 1995).
However, the participation of sympathetic fibers in nociception
mediated byB1 receptors activation during neuropathy still needs
to be determined.
Besides being caused by nerve injury, painful neuropathymay
also develop in diabetes (Woolf and Mannion, 1999; Sah et al.,
2003). It has been reported recently that thermal hyperalgesia in
diabetic mice was blocked by the systemic treatment with selec-
tive B1 receptor antagonists (Gabra and Sirois, 2002, 2003a,b).
Moreover, intrathecal administration of a B1 receptor agonist
produces thermal hyperalgesia in hyperglycemic rats (Couture et
al., 2001). Thus, the activation of B1 receptors is a critical step in
the production of neuropathic pain, and B1 receptor blockade
is able to not only prevent the development of nociception but
also reduce an established painful condition. Of interest are the re-
sults showing that oral treatment with the newly synthesized non-
peptide B1 receptor antagonist SSR240612 [(2R)-2-[((3R)-3-(1,3-
benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]
propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]
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phenyl)-N-isopropyl-N-methylpropanamide hydrochloride] was
able to reduce the thermal hyperalgesia produced by sciatic nerve
injury in rats (Gougat et al., 2004).These findings support thenotion
that the development of oral-selective B1 receptor antagonistsmight
be expected tohave clinical therapeuticpotential in themanagement
of neuropathic pain.
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